Immuno-agglutination particle suspensions

• US 4,582,810 A
• Filed: 09/30/1983
• Issued: 04/15/1986
• Est. Priority Date: 09/30/1983
• Status: Expired due to Fees

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Rosenstein, Robert
• Primary Examiner(s): Nucker, Christine M.
• Application Number:
  US06/537,737
• Time in Patent Office: 928 Days
• Field of Search: 436/501, 436/528, 436/531-534, 436/823, 436/548, 435/181
• US Class Current: 436/528
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: Y10S 436/823 Immunogenic carrier or carrier per se
• CPC Class Codes: Y10T 436/25875 Gaseous sample or with change of physical state

Abstract

A suspension of diagnostic particles comprising antibody molecules attached to a carboxylate derivatized polymer core is provided for agglutination tests. The antibody is linked to the core through an avidin-biotin bridge. Avidin is joined by an amide bond to carboxyl groups on the core, and biotin is linked by an amide bond to amino groups on the antibody molecule. The core-bound antibody is exposed to a mixture of free biotin and biotinylated antibody to attach a controlled amount of antibody that is consistent with suspension stability prior to its use in a test and rapid cross-linking of suspended particles in the presence of antigen.

Claims

1. A diagnostic particle comprising

a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter,

a plurality of avidin moieties linked through amide bonds to said core,

a plurality of biotin moieties complexed to said avidin moieties, and

a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties, the amount of antibody molecules on the surface of said particle being controlled so that said diagnostic particle may be stably suspended in aqueous medium in the presence of like particles without agglutination, but subsequently agglutinate in the presence of a substance with which said antibody molecules react.

25. A diagnostic particle in accordance with claim 1 wherein said particle has between about 2×

10¹¹ and about 2×

10¹² antibody molecules per cm² of surface area of said polymeric core.

26. A diagnostic particle in accordance with claim 1 wherein said antibody molecules are linked to a first significant portion of said biotin moieties and a second significant portion of said biotin moieties have no antibody molecules linked thereto.

2. A diagnostic composition comprising a plurality of particles, each particle comprising a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter, a plurality of avidin moieties linked through amide bonds to said core, a plurality of biotin moieties complexed to said avidin moieties and a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties and an aqueous medium in which said particles are suspended, the amount of antibody molecules on each of said particles being controlled so that said particles remain in suspension in said aqueous medium without agglutination, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.

3. A composition according to claim 2 wherein said particles cores are formed of a polymer selected from the group consisting of polyacrylamide and polystyrene.

4. A composition according to claim 2 wherein said particles have between about 10¹⁰ and about 10¹³ avidin molecules per cm² of surface area of said cores.

5. A composition according to claim 2 wherein said particles have between about 2×

10¹¹ and about 2×

10¹² antibody molecules per cm² of surface area of said cores.

6. A composition according to claim 2 wherein said diagnostic particles have neutralizing moieties attached to core surface carboxyl groups that are not linked by amide bonds to avidin.

7. A composition according to claim 2 wherein said diagnostic particles also include non-immunogenic proteinaceous material adsorbed on surfaces of said cores.

8. A composition according to claim 2 wherein said antibody molecules are monoclonal antibody molecules.

9. A composition according to claim 2 wherein said cores are carboxylated to between about 0.1 to about 0.5 milliequivalents per gram of core particles.

10. A method of preparing diagnostic particles comprising

providing carboxylate-derivatized polymeric core particles between about 0.2 and about 1.0 micron in diameter,

linking avidin molecules to said core particles through amide bonds,

binding biotin molecules to antibody molecules through amide bonds, and

complexing said core particle-linked avidin with a controlled amount of said antibody molecule-bound biotin, whereby said diagnotic particles may be suspended in aqueous medium without agglutination of said particles, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.

11. A method according to claim 10, providing core particles which are carboxylated to between about 0.1 and about 0.5 milliequivalents per gram of polymer.

12. A method according to claim 10 wherein said polymer is selected from the group consisting of polystyrene and polyacrylamide.

13. A method according to claim 12 wherein said polymer is polystyrene, and between about 1.2×

10^-3 and about 1.2×

10^-2 gm of avidin are linked per gram of core particles.

14. A method according to claim 12 wherein said polymer is polyacrylamide and between about 1.2×

10^-3 and about 1.2×

10^-2 gm of avidin are linked per gram of core particles.

15. A method according to claim 10 wherein said avidin is selected from the group consisting of egg white avidin and streptavidin.

16. A method according to claim 10 including neutralizing surface carboxyl groups of said core particles not bound to avidin.

17. A method according to claim 16 including adsorbing a non-immunogenic proteinaceous material onto the surface of said core particles subsequent to avidin linking and carboxyl group neutralization.

18. A method according to claim 10 controlling the amount of antibody molecules by complexing said core particle-linked avidin with a mixture of free biotinic acid and said antibody-bound biotin.

19. A method according to claim 18 controlling the amount of antibody molecules to provide between about 2×

10¹¹ and about 2×

10¹² antibody molecules per cm² of core particles surface area.

20. A method according to claim 19 wherein the molar ratio of said biotinic acid and said antibody-bound biotin is between about 1:

1 and about 10;

1.

21. A method according to claim 10 wherein said antibody is a monoclonal antibody.

22. A method according to claim 10 wherein linking said avidin to said core particles comprises reacting said core particles with a carbodiimide to form an intermediate and reacting said intermediate with avidin.

23. A method according to claim 22 wherein linking said biotin to said antibody comprises reacting said antibody with an N-hydroxy imide to form an ester intermediate and reacting said antibody with said ester intermediate.

24. A method according to claim 10, including suspending said diagnostic particles in a liquid medium to form a stable suspension.

27. A diagnostic particle comprising

a core between about 0.2 and about 1.0 micron in diameter formed of polymer selected from the group consisting of polyacrylamide and polystyrene, said polymer being carboxylated to between about 0.1 to about 0.5 milliequivalents per gram,

between about 10¹⁰ and about 10¹³ avidin molecules bound through amide bonds to said core per cm² of surface area,

neutralizing moieties attached to core surface carboxyl groups that are not linked by amide bonds to avidin,

additional non-immunogenic proteinaceous material adsorbed on surfaces of said cores,

biotin moieties complexed to said avidin moieties, and

about 2×

10¹¹ and about 2×

10¹² antibody molecules linked through amide bonds to biotin moieties per cm² of surface area of said core.

28. A suspension of diagnostic particles in accordance with claim 27 in an aqueous medium.